Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant stock increase of over 10%, currently trading at 13.95 HKD with a transaction volume of 32.66 million HKD, following the announcement of priority review for its drug application [1] Group 1 - On January 6, the CDE website indicated that Tongyuan Kang Pharmaceutical's application for Tyrosine Kinase Inhibitor (TY-9591) is proposed for priority review [1] - The drug is intended for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastasis [1] - In September of the previous year, at the World Lung Cancer Conference, the key Phase II clinical trial results of TY-9591 for NSCLC brain metastasis garnered significant attention from peers [1]
港股异动 | 同源康医药-B(02410)最高涨超10% TY-9591片拟纳入优先审评